Pankaj Patel is an Indian pharmaceutical business leader whose career has closely followed the transformation of the Indian pharmaceutical industry. He joined his family’s pharmaceutical business in 1976 and later took charge of the company that became Zydus Lifesciences.
Over the following decades, the business expanded beyond its original pharmaceutical base. It moved into research, consumer healthcare, biotechnology and international markets.
Today, Patel serves as Chairman of Zydus Lifesciences, a global life sciences company with operations across international markets. His work also extends beyond the company. He has held leadership positions in business, education and healthcare institutions, including IIM Ahmedabad and the Reserve Bank of India’s Central Board.
Quick Overview
| Field | Details |
|---|---|
| Full Name | Pankaj Ramanbhai Patel |
| Age | 73 Years (as 2026) |
| Born | 16 March 1953, Bhadran, Gujarat, India |
| Education | B.A., M.Pharm, LLB |
| Occupation | Businessman |
| Known For | Chairman, Zydus Lifesciences; Former President, FICCI |
| Spouse | Priti Patel |
| Children | 2 |
Pankaj Patel’s Early Connection With Pharmaceuticals
Pankaj Ramanbhai Patel was born on March 16, 1953. His father, Ramanbhai B. Patel, founded Cadila Laboratories in 1952. The company later became the foundation of the Zydus business.
Patel studied pharmacy at L.M. College of Pharmacy in Ahmedabad. He completed his Master’s in Pharmaceutics in 1976 and later undertook executive education in management studies at IIM Ahmedabad.
His connection with the family business began well before he formally joined it. Growing up around pharmaceutical manufacturing gave him an early understanding of the industry.
In 1976, he joined Cadila Laboratories professionally. His pharmaceutical education and practical business experience shaped his approach to the company.
Pankaj Patel’s Journey with Cadila Healthcare
A major turning point came in 1995, when the original Cadila business was restructured.
The change followed the separation of the Patel and Modi families. Cadila Healthcare emerged as the Patel family’s pharmaceutical business, while Cadila Pharmaceuticals became the other company.
Patel became Managing Director of Cadila Healthcare and the Zydus Group.
The restructuring gave him an opportunity to build a distinct pharmaceutical organisation. Under his leadership, the company increasingly focused on research, product development and manufacturing capabilities.
This approach later became one of the defining features of the Zydus business.
From Cadila Healthcare to Zydus Lifesciences
Over the years, the company expanded across pharmaceuticals, consumer healthcare, biotechnology and other areas of life sciences.
Its portfolio also moved beyond prescription medicines. Consumer brands such as Sugar Free and Everyuth helped the company reach a much wider consumer base.
Research became another important part of the company’s strategy. Zydus developed products across multiple therapeutic areas and invested in research-driven medicines.
One notable example is Saroglitazar. It was developed for the treatment of diabetic dyslipidemia and is marketed in India under the brand name Lipaglyn.
The company also expanded internationally, including in major pharmaceutical markets such as the United States.
In 2022, Cadila Healthcare was renamed Zydus Lifesciences. The new identity reflected the organisation’s broader focus across life sciences.
Today, Zydus describes itself as a discovery-driven global life sciences company. IIM Ahmedabad’s official profile of Patel states that the company operates across 55 countries.
Research Became Central to Patel’s Business Strategy
For Patel, pharmaceutical growth has involved more than expanding manufacturing capacity. Research and innovation have remained important parts of the Zydus strategy.
His official profile notes more than 100 research papers and more than 64 patents associated with his work as a co-inventor.
The company’s research capabilities became particularly visible during the COVID-19 pandemic.
Zydus developed ZyCoV-D, a DNA-based COVID-19 vaccine. The vaccine received emergency-use authorisation in India in 2021.
It became one of the company’s most visible research milestones during the pandemic. The development also highlighted the growing role of Indian pharmaceutical companies in vaccine research and technology.
Patel had previously spoken about Zydus’s experience with vaccine development, including work related to H1N1. This experience preceded the company’s COVID-19 vaccine programme.
Pankaj Patel’s Leadership Beyond Zydus
Patel’s professional involvement extends beyond his role at Zydus.
He is a past president of the Federation of Indian Chambers of Commerce & Industry (FICCI). He has also been involved with the Indian pharmaceutical industry’s institutional ecosystem.
Education has become another important part of his public leadership.
In November 2022, Patel became Chairperson of the Board of Governors of IIM Ahmedabad. He had previously served on the institute’s Board of Governors for eight years.
He has continued to participate in major institutional events, including IIM Ahmedabad’s 2026 annual convocation.
The institute’s current profile identifies him as Chairman of Zydus Lifesciences and Chairman of IIM Udaipur. It also notes his role as a part-time non-official Director on the Central Board of the Reserve Bank of India.
These roles have given Patel influence across business, management education and economic institutions.
Healthcare and Institution Building
Patel’s involvement in healthcare extends beyond Zydus’s corporate operations.
He is associated with the Gujarat Cancer Society and serves as Chairman of the Gujarat Cancer and Research Institute. The institution provides cancer treatment and serves patients across the region, including those from economically weaker sections.
Patel is also associated with the Zydus Foundation. The foundation has established Zydus Hospital and Medical College in Dahod.
His work across these institutions connects several areas that have remained important throughout his career: pharmaceuticals, healthcare, education and research.
Recognition for His Contribution to Healthcare
Patel has received recognition for his contribution to pharmaceuticals and entrepreneurship.
His honours include the Acharya P.C. Ray Memorial Gold Medal Award, the Eminent Pharmacist Award and the India Innovator Award at the India Business Leaders Awards.
He was also recognised with the Ernst & Young Entrepreneur of the Year Award in the Life Sciences category.
In 2025, the Government of India conferred the Padma Bhushan on Pankaj R. Patel for his contribution to the healthcare sector.
The official Padma Awards citation describes him as Chairman of Zydus Lifesciences. It also highlights his work in pharmaceutical innovation and healthcare.
The honour added a national recognition to a career spanning pharmaceutical business, research, healthcare and institutional leadership.
Pankaj Patel‘s Next Chapter of Zydus
The pharmaceutical environment Zydus operates in today is very different from the one Patel entered in 1976.
The business has grown from its original manufacturing base into research, specialty products, vaccines, consumer healthcare and international markets.
Leadership at the company is also increasingly being shared with the next generation.
Patel’s son, Dr. Sharvil Patel, serves as Managing Director of Zydus Lifesciences. Pankaj Patel continues as Chairman.
This marks another stage in the family’s business journey. The next generation now has a larger role in the company’s leadership.
For Zydus, the challenge is to continue investing in research and innovation. At the same time, it must compete in highly regulated pharmaceutical markets around the world.
For Patel, the larger story is the evolution of a family pharmaceutical company into a diversified life sciences organisation.
Why Pankaj Patel Matters to the Zydus Story
Pankaj Patel’s significance lies in the scale and duration of his involvement with the pharmaceutical business.
He entered Cadila in 1976 and took charge following the 1995 restructuring. Over the following decades, he expanded the business across products, research and international markets.
The journey from Cadila Healthcare to Zydus Lifesciences also reflects a wider change within Indian pharmaceuticals.
Companies that once focused largely on domestic manufacturing have increasingly moved into research, complex medicines, biotechnology, vaccines and global markets.
Patel’s career has developed alongside that transition.
His professional story is closely tied to several institutions. At Zydus, his work has centred on pharmaceuticals and research. His wider roles have taken him into business organisations, education and healthcare.
As Zydus enters its next phase under a new generation of leadership, Pankaj Patel remains Chairman of the company. He also continues to hold significant institutional responsibilities.
His story is ultimately about the long-term development of an Indian pharmaceutical enterprise into a global life sciences organisation.
FAQs
What is Pankaj Patel known for?
Pankaj Patel is best known for leading the growth of Cadila Healthcare, which later became Zydus Lifesciences, into a diversified global life sciences company.
When did Pankaj Patel join Cadila?
Pankaj Patel joined Cadila Laboratories in 1976 after completing his pharmaceutical education.
Who founded Cadila Laboratories?
Ramanbhai B. Patel founded Cadila Laboratories in 1952. The company later became the foundation of the Zydus business.
What is Pankaj Patel’s current role?
Pankaj Patel is the Chairman of Zydus Lifesciences. He also serves as Chairperson of the Board of Governors of IIM Ahmedabad.
What is Zydus Lifesciences known for?
Zydus Lifesciences operates across pharmaceuticals and broader life sciences. Its activities include research, manufacturing, consumer healthcare and vaccines.
Did Zydus develop a COVID-19 vaccine?
Yes. Zydus developed ZyCoV-D, a DNA-based COVID-19 vaccine that received emergency-use authorisation in India in 2021.
